Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
出版年份 2021 全文链接
标题
Understanding the place for
GLP‐1RA
therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 23, Issue S3, Pages 40-52
出版商
Wiley
发表日期
2021-09-14
DOI
10.1111/dom.14500
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Type-2 diabetes patients at high risk for cardiovascular events: time to challenge the ‘metformin-always first’ paradigm
- (2021) Victor Aboyans et al. European Journal of Preventive Cardiology
- Gaps in Evidence‐Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease
- (2021) Adam J. Nelson et al. Journal of the American Heart Association
- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
- (2021) Alessandro Mantovani et al. Metabolites
- Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
- (2021) Salim S. Virani et al. CIRCULATION
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes
- (2021) John B. Buse et al. DIABETES OBESITY & METABOLISM
- CARDIOLOGIST USE OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS SINCE RELEASE OF FAVORABLE CARDIOVASCULAR OUTCOMES TRIALS: A NATIONAL STUDY
- (2021) Rishav Adhikari et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England
- (2021) Kamlesh Khunti et al. Lancet Diabetes & Endocrinology
- Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care
- (2021) Caitlin Colling et al. DIABETES CARE
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
- (2021) Hertzel C. Gerstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- How glucagon-like peptide 1 receptor agonists work
- (2021) Christine Rode Andreasen et al. Endocrine Connections
- Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
- (2020) Jakob S. Knudsen et al. PLoS One
- Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus
- (2020) Valeria Raparelli et al. Journal of the American Heart Association
- Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials
- (2020) Lisa Ludwig et al. Cardiovascular Diabetology
- Number needed to treat in cardiovascular outcome trials of glucagon‐like peptide‐1 receptor agonists: A systematic review with temporal analysis
- (2020) Melanie J. Davies et al. DIABETES OBESITY & METABOLISM
- 624-P: Primary Care Education Leads to Improved Diabetes Knowledge and Clinical Practice
- (2020) RYAN WOOLLEY et al. DIABETES
- Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management
- (2020) Giulia Ferrannini et al. DIABETES CARE
- Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
- (2020) Matthew J. Crowley et al. DIABETES CARE
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
- (2020) Lorraine Lipscombe et al. Canadian Journal of Diabetes
- Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy
- (2020) Chintan V. Dave et al. CIRCULATION
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
- (2020) M. Angelyn Bethel et al. DIABETES CARE
- Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019
- (2020) Kristian L. Funck et al. DIABETES OBESITY & METABOLISM
- Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
- (2020) Brent A McLean et al. ENDOCRINE REVIEWS
- Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin
- (2020) Giulia Ferrannini et al. EUROPEAN HEART JOURNAL
- Effect Of Metformin On All-Cause Mortality And Major Adverse Cardiovascular Events: An Updated Meta-Analysis Of Randomized Controlled Trials
- (2020) Matteo Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management
- (2020) Naresh Kanumilli et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis
- (2019) Lana C. Pinto et al. Scientific Reports
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists
- (2019) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Use of Guideline-Recommended Risk-Reduction Strategies Among Patients with Diabetes and Atherosclerotic Cardiovascular Disease: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)
- (2019) Suzanne V. Arnold et al. CIRCULATION
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Antidiabetic Utilization and Expenditure in Denmark: A 22‐Year Nationwide Study
- (2019) Camilla Bang et al. DIABETES OBESITY & METABOLISM
- WITHDRAWN: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition
- (2019) Pouya Saeedi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Implications of Specialist Density for Diabetes Care in the United States
- (2019) Ravi B. Patel et al. JAMA Cardiology
- Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension
- (2019) Johanna Helmstädter et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases
- (2019) Anders Jorsal et al. EUROPEAN HEART JOURNAL
- MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
- (2019) Michael A Nauck et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- An overview of GLP-1 agonists and recent cardiovascular outcomes trials
- (2019) Kelsey H Sheahan et al. POSTGRADUATE MEDICAL JOURNAL
- Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
- (2019) Marco Castellana et al. Scientific Reports
- Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
- (2018) Charlotte Granhall et al. CLINICAL PHARMACOKINETICS
- Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
- (2018) Tina Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
- (2018) Rodrigo Oliveira Moreira et al. Diabetology & Metabolic Syndrome
- Recent updates on GLP-1 agonists: Current advancements & challenges
- (2018) Dilip Sharma et al. BIOMEDICINE & PHARMACOTHERAPY
- New avenues in the regulation of gallbladder motility - implications for the use of glucagon-like peptide-derived drugs
- (2018) Ida M Gether et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
- (2018) Guntram Schernthaner et al. Cardiovascular Diabetology
- Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
- (2018) Charlotte Granhall et al. CLINICAL PHARMACOKINETICS
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes
- (2017) Mary E. Herman et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom
- (2017) Lei Qin et al. Diabetes Therapy
- Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom
- (2017) Lei Qin et al. Diabetes Therapy
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
- (2016) Julio Rosenstock et al. DIABETES CARE
- Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
- (2016) J. Skov et al. DIABETES OBESITY & METABOLISM
- A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients
- (2016) Mirna S. Abd El Aziz et al. DIABETES OBESITY & METABOLISM
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
- (2016) Karolin Bettge et al. DIABETES OBESITY & METABOLISM
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
- (2016) Robert A. Scott et al. Science Translational Medicine
- Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials
- (2015) Jeanne S. Geiser et al. CLINICAL PHARMACOKINETICS
- Association of Cardiometabolic Multimorbidity With Mortality
- (2015) Emanuele Di Angelantonio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
- (2014) John B. Buse et al. DIABETES CARE
- Changes in Diabetes-Related Complications in the United States, 1990–2010
- (2014) Edward W. Gregg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
- (2014) Stephen C L Gough et al. Lancet Diabetes & Endocrinology
- Prognostic Significance of Silent Myocardial Infarction in Newly Diagnosed Type 2 Diabetes Mellitus
- (2013) Timothy M.E. Davis et al. CIRCULATION
- Epidemiology of Diabetes and Diabetes Complications in the Elderly: An Emerging Public Health Burden
- (2013) Mark Corriere et al. Current Diabetes Reports
- Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
- (2013) O. J. Phung et al. DIABETIC MEDICINE
- Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia
- (2012) Jacob Lønborg et al. Circulation-Cardiovascular Interventions
- Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study
- (2012) DIABETES CARE
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Relationship between glycated haemoglobin and microvascular complications: Is there a natural cut-off point for the diagnosis of diabetes?
- (2009) C. Sabanayagam et al. DIABETOLOGIA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now